Mice C57BL/6, P14 TCR-transgenic (Tg)45, pmel TCR-Tg46 and Rosa26-Cas9 knock-in47 mice were purchased from the Jackson Laboratory. Human CD19 CAR-Tg mice were provided by T. Geiger36. We crossed Rosa26-Cas9 knock-in mice with P14, pmel or human CD19 (hCD19) CAR-Tg mice to express Cas9 in antigen-specific CD8+ T cells. The Cas9-expressing mice were fully backcrossed to
Clinical trial design, patients and conduct The Algonquin study is an ongoing, multicentre, open-label, single-arm, two-part study (ClinicalTrials.gov identifier: NCT03715478)) of BPd in patients with relapsed/refractory MM. Part 1 of the trial consisted of a dose-exploration phase22. Part 2 is evaluating the safety, tolerability and clinical activity of the dose and schedule identified in part 1. Patients included
Animals SPF WT C57BL/6J (JAX, 000664) mice were obtained from The Jackson Laboratory. The following strains were also purchased from The Jackson Laboratory: Il21-VFP (B6.Cg-Il21tm1.1Hm/DcrJ, JAX, 030295)35, Il21r-knockout (B6.129-Il21rtm1Kopf/J, JAX, 019115)36, OT-II (B6.Cg-Tg(TcraTcrb)425Cbn/J, JAX, 004194)37, MD4 (C57BL/6-Tg(IghelMD4)4Ccg/J, JAX:002595)38, Jchain-creERT2 (B6(129)-Jchainem1(icre/ERT2)Deep/J, JAX, 035764)39, ROSA-DTA (B6.129P2-Gt(ROSA)26Sortm1(DTA)Lky/J, JAX, 009669)40, Ai9 (B6.Cg-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J, JAX, 007909)41, Thy1.1 (B6.PL-Thy1a/CyJ, JAX, 000406), AID-cre
